Allicin inhibits mouse colorectal tumorigenesis through suppressing the activation of STAT3 signaling pathway

Area of Science:

• Oncology
• Natural Compounds
• Gastroenterology

Background:

• Allicin is a key active compound in garlic with known in vitro anti-cancer properties.
• Previous research indicates Allicin inhibits colorectal cancer cell proliferation and promotes apoptosis.
• The in vivo efficacy of Allicin against colorectal cancer remains largely unverified.

Purpose of the Study:

• To investigate the anti-colorectal cancer effects of Allicin in a mouse model.
• To explore the molecular mechanisms underlying Allicin's action against colorectal cancer.
• To evaluate Allicin as a potential therapeutic supplement for colorectal cancer.

Main Methods:

• Utilized the azoxymethane/dextran sodium sulfate (AOM/DSS) induced colorectal cancer mouse model for in vivo studies.
• Conducted in vitro experiments using HCT116 colorectal cancer cells to assess Allicin's effects on apoptosis, survival, and proliferation.
• Analyzed the molecular mechanisms, focusing on the STAT3 signaling pathway.

Main Results:

• Allicin significantly inhibited colonic tumorigenesis in the AOM/DSS mouse model.
• In vitro, Allicin promoted apoptosis and suppressed the survival and proliferation of HCT116 cells.
• The anti-cancer effects of Allicin were associated with the suppression of STAT3 signaling activation.

Conclusions:

• Allicin demonstrates significant in vivo efficacy in inhibiting colorectal cancer.
• Allicin exerts its anti-cancer effects by promoting apoptosis and suppressing cell survival and proliferation, partly via STAT3 pathway inhibition.
• These findings support Allicin's potential as a favorable dietary supplement for human colorectal cancer management.